Conclusion générale
L'activité hémolytique est également
déterminée chez toutes les souches de Candida. Une
activité ß-hémolytique est développée
après une lyse totale des érythrocytes du sang du
mouton. Ainsi, il est intéressant de souligner
l'importance de l'élément fer dans le
métabolisme des
Candida. L'étude des caractères enzymatiques aux
galeries Api Zym a permis de détecter 19 enzymes chez les
différentes souches de Candida testées. La
présence des enzymes varie d'une souche à une autre .Les enzymes
les plus détectées sont l'Estérase (C4), la Valine
arylamidase, la Cystine arylamidase et le Naphtol-AS-BI phosphohydrolase chez
toutes les espèces testées.
La troisième partie concerne l'étude qualitative et
quantitative de la formation de
biofilm
L'étude qualitative de la formation de biofilm faite
par la coloration à la safranine montre que la majorité des
isolats sont moyennement formatrice de biofilm et pour la culture sur milieu au
rouge Congo la totalité des souches n'est pas productrice de biofilm.
L'étude quantitative de la formation de biofilm par le
test de hydrophobicité indique que le cyclohexane et l'xylène
peuvent s'adhérer aux différentes souches de Candida
avec des degrés différents. Aussi, concernant
l'adhésion et l'implication des isolats de Candida dans la
formation de biofilm sur les plaques ELISA, notre étude a bien
confirmé que ce facteur
(l'adhésion) est variable selon les espèces.
RÉFÉRENCES
BIBLIOGRAPHIQUES
Page 1
Références
Bibliographiques
1- Abu-Elteen, K.H.; Abu-Elteen, R.M. (1998). The prevalence
of Candida albicans population in the mouths of complete denture
wearer's. New Microbiol, 21:41-48.
2- Aoki, S.; Ito-Kuwa, S.; Nakamura, Y.; Masuhara, T. (1990).
Comparative pathogenicity of wild-type strain and respiratory mutants of
Candida albicans in mice. Zol.Bakt,
273:332-343.
3- Arendorf, T.M.; Walker, D.M. (1980).The prevelance and
intra-oral distribution of Candida albicans in man. Arch
.Oral Biol, 25:1-10.
4- Baillie, G.S.; Douglas, L.J. (1999a). Role of dimorphisim
in development of Candida albicans biofilm. J. Med
Microbiol, 48(7):671-679.
1- Banerjee, S.N.; Emori, T.G.; Culver, D.H.; Gaynes, R.P.;
Jarvis, W.R.; Horan, T. (1991). Secular trends in nosocomial primary blood
stream infections in the United States. Am .J. med,
91: 86-89.
2- Baillie, G.S.; Douglas, L.J. (1999a). Role of dimorphisim
in development of Candida albicans biofilm. J. Med
Microbiol, 48(7): 671-679.
3- Beck-Sague, C.M.; Jarvis, T.R. (1993) Secular trends in
the epidemiology of nosocomial fungal infection in the United States.
J. Infect . Dis, 167: 1247-1251.
4- Budtz-Jorgensen, E. (2000). Ecology of Candida-associated
denture stomatitis. Microb. Ecol. Health Dis,
12:170-185.
5- Cannon, R.D.; Chaffin, W.L (1999). Oral colonization
by Candida albicans. Critical review in Oral Biology and
Medicine, 10:359-383.
6- Chaffin, W.L.; López- Ribot, J.L.; Casanova, M.;
Gozalba, D .and Martinez, J.P. (1998). Cell wall and secreted proteins of
Candida albicans: identification, function and expression.
Microbiology and molecular Biology Review,
62:130-180.
7- Calderone, R.D.; Fonzi, W.A (2001). Virulence factors
of Candida albicans. Trends Microbiol, 9(7):
327-335.
8- Calderone, R.A. (2002). Taxonomy and biology of
Candida. In: Calderone, R.A. (Eds). Candida and Candidiasis,
ASM Press, Washington D .C, pp15-27.
9- Cerikçio lu, N.; Ilki, A .; Bilgen, H.; Ozek, E.;
Metin, F.; Kalaça, S. (2004). The relationship between candidemia and
candidal colonization and virulence factors of the colonizing strains in
preterm infants. Turk J Pediatr.46(3):245-50.
10- Chabasse, D.; Guiguen, C.P.; Contet-Audonneau, N.
(1999).Mycologie Médicale. Paris : Masson
Page 2
Références
Bibliographiques
11- Chandra, J.; Kuhn, D.M.; Mukhergee, P.K.; Hoyer, L.L.;
McCormick, T.; Ghannoum, M.A. (2001a) .Biofilm formation by the fungal
pathogen Candida albicans: development, architecture, and drug
resistance. J. Bacteriol., 183(18): 5385-5394.
12- Chandra, J.; Mukhergee, P.K.; Leidich, S.D.; Faddoul, F.F.;
Hoyer, L.L.; Douglas, L.J.; Ghannoum, M.A .(2001b). Antifungal resistance of
candidal biofilms formed on denture acrylic in vitro. J. Dent.
Res, 80:903-908.
13- Chen, H.; Fujita, M.; Feng, Q.; Clardy, J.; Fink, G.R.
(2004). Tyrosol is a quorum-sensing molecule in Candida albicans.
Proc .Nat .Acad .Sci, 101(14): 5048-52.
14- Colombo, A.L.; Guimaraes, T. (2003). Epidemiology of
hematogenous infections due to Candida spp. Rev .Soc .Bras
.Med .Trop, 36(5):599-607.
15- Costerton, J.W.; Stewart, P.S.; Greenberg, E.P (1999).
Bacterial biofilms: a common cause of persistent infections.
Science, 284:1318-1322
16- Costa, A.; Costa, C.; Misefari, A.; Amato, A. (1968). On the
enzymatic activity of certain fungi .VII.Phosphatidase activity on media
containing sheep's blood of pathogenic strains of Candida albicans.
Atti Soc .Sci .Fic .Mat .Nat, 14:93-101.
17- Da, CostaKRC.; Ferreira J.C.; Komesu, M.C.; Candida R.C.
(2009). Candida albicans and Candida tropicalis in oral
candidosis: quantitative analysis, exoenzyme activity, and antifungal drug
sensitivity. Mycopathologia; 167:73-9.
18- Dag, I.; Kiraz, N.Oz Y (2010). Evaluation of different
detection methods of biofilm formation in clinical Candida isolates.
African Journal of Microbiology Research, 4(24),
pp.
19- Devenport, D.S.; Massanari, R.M.; Pfaller, M.A.; Bale, M.J.;
Streed, S.A.;,Hierholzer W.J (1986). Usefulness of a test for slime production
as a marker for clinically significant infections with coagulase-negative
staphylococci. J. Infect. Dis.,153: 332339.
20- Donlan, R.M (2001a). Biofilm formation: a clinically
relevant microbiological process. Clin. Infect. Dis,
33:1387-1392.
21- Donlan, R.M (2001b). Biofilms and device -associated
infection. Emerg. Infect. Dis, 7:277-281.
22- Douglas, L.J. (2003). Candida biofilms and their
role in infection. Trends Microbiol, 11 (1):
30-36.
23- Farah, C.S.; Ashman, R.B.; Challacombe, S.J. (2000). Oral
Candidosis. Clinicsin Dermatology,18(5):553-562.
Page 3
Références
Bibliographiques
24- Farina, C.; Saleri, N.; Lombart JP, et al. (2009).
Epidemiological phenotypic characteristics of vaginal yeasts at the Comoros.
Mycoses, 52:458-461.
25- Gang, L.; Samaranayake, L.P.; Yau, J.Y. (2001).
Candida Species Exhibit Differential in Vitro Hemolytic Activities.
J .Clin Microb, 39(8):2971-2974.
26- Garber. (2001) .An overview of fungal infection
.Drugs, 61(1):1-12.
27- Gokce, G.; Cerikcioglu N.; Yagci, A. (2007). Acid
proteinase, phospholipase, and biofilm production of Candida species
isolated from blood cultures .Mycopathol Mycol Appl
164(6):265-9.
28- Hay, R.J. (1999). The management of superficial
candidaisis .J. Am .Acad.Dermatol., 40:535-542.
29- Hawser, S.P.; Douglas, L.J. (1994).Biofilm formation
by Candida species on the surface of catheter materials in vitro
.Infect .Immun, 62(3):915-921.
30- Hawser, S.P.; Baillie, G.S.; Douglas, L.J. (1998a).
Production of extracellular matrix by Candida albicans biofilms
.J.Med .Microbiol,
47(3):253-256.
31- Hawser, S.P.; Norris. H.; Jessup, C.J.; Ghannoum, M.A.
(1998b). Comparison of 2,3-bis(2-methoxy -4-nitro-5-sulfophenyl)-5-[(
phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with
the standardized National Committee for Clinical Laboratory Standards method of
testing clinical yeast isolates for susceptibility to antifungal
agents. J.Clin .Microbiol, 36:1450-1452.
32- Horn, R.; Wong, B.; Kiehn, T.E.; Armstrong, D. (1985).
Fungemia in a cancer hospital: changing frequency, earlier onset, and results
of therapy .Rev.Infect .Dis , 7:646-655.
33- Hube, B. (1998). Possible role of proteinases in
Candida infections .Rev. Iberoam.Micol,
15:68-71.
34- Ibrahim, A.S.; Mirbod, F.; Filler, S.G.; Banno, Y.; Cole,
G.T.; Kitajima, Y., Edwards, J.E.; Nozawa, y.; Ghannoum , M.A. (1995). Evidence
implicating phospholipase as a virulence factor of Candida albicans
.Infect .Immun, 63:1993-1998.
35- Johnson, E.M.; Warnock, D.W.; Luker, J., Porter, S.R.and
Scully, C. (1995). Emergence of azole drug resistance in Candida species from
HIV-infected patients receiving prolonged fluconazole therapy for oral
candidiasis .J.Antimicrob .Chemother, 35:103-104.
36- Kalfa, V.C.; Roberts, R.L.; Stiehm, E.R.(2003). The
sundrome of chronic mucocutaneous candidiasis with selective antibody
deficiency .Ann. Allergy Asthma
Immunol, 90(2):259-64.
Page 4
Références
Bibliographiques
37- Kaloterakis, A.; Rizos, I.; Goumas, G.; Filiotou , A.;
Barbetseas ,J.; Papathanasiou ,P.(2003). Isolated native tricuspid valve
Candida endocarditis in a non - drug-addicted patient: case report and
review of the literature .J. Heart V alve Dis., 12
(5): 652-8.
38- Khardori, N.; Yassien, M. (1995).Biofilm in
device-related infection .J. Ind .Microbiol,
15:141-147.
39- Kitchen, V.S.; Savage, M.; Harris, J.R. (1995).
Candida albicans resistance in AIDS. J. Infect.
Dis, 22:204-205.
40- Kunkel. D.; Sari- Belkaroubi.; Boucherit, K.; Seddiki,
S.M.L.; Boucherit-Atmani, Z(2011). Les biofilm de Candida albicans
formée dans les catheters et des sondes et leurs resistance à
l'amphotèricine B .
41- Klipser, M.E.; Lewis, R.E.; Pfaller, M.A (1998). Therapy
of Candida infection: susceptibility testing resistance and
therapeutic option .Ann. Pbarmacotber, 32:
1353-1361.
42- Kojic, E.M.; Darouiche, R.O. (2004). Candida
infections of medical devices .Clin .Microbiol. Rev.,
17(2): 255-267.
43- Kuhn, D.M.; George, T.; Chandra, J.; Mukherjee, P.K.;
Ghannoum, M.A. (2002). Antifungal susceptibility of Candida biofilm:
unique efficacy of amphotericin B lipide formulation and echinocandins.
Antimicrob. Agent Chemother, 4 6:1773-1780.
44- Kumamoto, C.A. (2002). Candida biofilms
Curr.Opin. Microbiol, 5: 608-611.
45- Leclerc et Bonneau (1982). La lixiviation : Source,
composition et atténuation eau du Québec, 15
(1),37-44.
46- Li, X., Yan, Z.and Xu, J. (2003). Quantitative variation
of biofilms among strains in natural population of Candida albicans.
Microbiology, 149(2):353-362.
47- Macfarlane, T.W.; Samaranayake, L.P (1989). Fungal
infection .In: clinical oral microbiology. London:
Wright: 122-139.
48- Emira Noumi.; Mejdi Snoussi.; Saghrouni F.; Ben Said M.;
Del Castillo L.; Valentin E.; Bakhrouf A (2009). Molecular typing of
clinical Candida strains using random amplified polymorphic DNA and
contour-clamped homogenous electric fields electrophoresis .Journal
of Applied Microbiology, 107:1991-2000.
49- Emira Noumi.; Mejdi Snoussi .; Hajer Hentati . ; Rafael
Sentandreu. ; Lucas del Castillo. ; Amina Bakhrouf. ; Eulogio Valentin
(20011a). Virulence properties and random amplification of polymorphic DNA
(RAPD) fingerprinting of Candida
Page 5
Références
Bibliographiques
albicans isolates obtained from Monastir dental
hospital, Tunisia. African Journal of Biothechnology,
10(6):905-912.
50- Emira Noumi.; Mejdi Snoussi.; Najla Trabelsi. ; Riadh
Ksouri . ; Amina Bakhrouf (2012). Antioxidant activities and RF-HPLC. ;
identification of polyphenols in the ethyl acetate extract of Tunisian Juglans
regia L treated barks .Journal of Medicinal plants Research , Vol
.6(xx),pp.xxx-xxx23February.; 2012.
51- Emira Noumi.; Mejdi Snoussi.; Kammoun Dorra.; Amina
Bakhrouf. ; Eulogio Valentin (2011). Comparison of the adhesion ability of
Candida albicans strains to biotic and abiotic surfaces.
African Journal of Biotechnology, 10(6): 977-985.
52- Manns, J.M.; Mosser, D.M.; Buckley, H.R (1994)
.Production of a hemolytic factor by Candida albicans
.Infect. Immun, 62: 5154-5156.
53- McCullough, M.J.; Ross, B.C.; Reade, P.C
(1996).Candida albicans: a review of its history, taxonomy,
epidemiology, virulence attributes, and methods of strain differentiation
.Int.J.Maxillofoc. Surg, 25:136-144.
54- Maertens, J.; Vrebos, M.; Boogaerts, M. (2001). Assessing
risk factors for systemic fungal infection .Eur.J. Cancer
Care, 10 (1):56-62.
55- Melo, A.S.A.; Padovan , A.C.B .; Serafim,R.C.; Puzer , L
.; Carmona , A.K.; Juliano Neto , L .; Brunstein 1 ,A.; Briones , M.R.S
(2006).The Candida albicans AAA ATPase homologue of Saccharomyces
cerevisiae Rix7p (YLL034c) is essential for proper morphology , biofilm
formation and activity of secreted aspartyl proteinases . Genet.
Mol. Res., 5 (4): 664 - 687.
56- Naglik, J.R.; Challacombe, S.J.; Hube, B. (2003)
Candida albicans secreted aspartyl proteinases in virulence and
pathogenesis .Microbiol .Mol .Biol .Rev, 67(3):
400-428.
57- Noumi, E.; Snoussi, M.; Hentati, H.; Mahdouani, K.; del
Castillo, L.; Valentin, E.; Sentandreu, R.; Bakhrouf, A. (2010). Adhesive
properties and Hydrolytic Enzymes of Oral Candida albicans strains.
Mycopathologia, 169: 269-278.
58- Tizaoui Ch.; Bouselmi L.; Mansouri L.; and Ghrabi A.
(2007). Landfill leachate treatment withozone and ozone/hydrogenperoxide
systems. Journal of Hazardous Materials, 140,
316-324.
59- Odds, F.C. (1988). Candida and Candidosis
.A review and bibliography .2nd and. London: Baillière
Tindall, 42-59. (Öman et Junestedt, 2008;
Öman et Hynning, 1993)
Page 6
Références
Bibliographiques
60- Odds. ; berneart (1994). Evaluation of CHROMagar
Candida for presumptive identification of clinically important
Candida species. Diagnostic Microbiologiy and infectious
Disease, 201-204.
61- Ozanne F. (1990). Les lixiviats de décharge. Le
point des connaissances en 1990. Techniques sciences.
L'eau, 6, 289-314.
62- Price, M. F.; Wilkinson, I.D.; Gentry, L.O. (1982). Plate
method for detection of phospholipase activity in Candida albicans.
Sabouraudia, 20: 7-14.
63- Pronost R. ; Matejka G., Les lixiviats de
décharges d'ordures ménagères. Production,
caractérisation, traitement, Environnement &
Technique. 196 (2000) 25-29.
64- Pfaller, M.A.; Diekema, D.J.; Jones, R.N. (2001).
International surveillance of bloodstream infection due to Candida
species: frequency of occurrence and in vitro susceptibilities to fluconazole,
ravuconazole and voriconazole and voriconazole of isolates collected from 1997
through 1999 in the SENTRY antimicrobial surveillance program .J.
Clin .Microbiol, 39:3254-3259.
65- Pfaller, M.A.; Diekema, D.J. (2002). Role of Sentinel
surveillance of Candidemia: trends in species distribution and
antifungal susceptibility .J. Clin
.Microbiol, 40: 3551-3557.
66- Pfaller, M.A.; Diekema, D.J.; Colombo, A.L.; Kibble, C.,
Ng, K.P.; Gibbs, D.L.; Newell, V.A. (2006).Candida rugosa, an emerging
fungal pathogen with resistance to azoles: geographic and temporal trends from
the ARTEMIS DISK antifungal surveillance program. J.Clin
.Microbiol, 44(10):3578-3582.
67- Ramage, G.; Walle, K.V.; López-Ribot, J.L. (2001).
Biofilm formation by Candida dubliniensis .Journal of
Clinical Microbiology, 39:3234-3240.
68- Ramage, S.S.; Walle, K.V.; Lopez-Ribot, J.L.
(2005).Candida biofilm: an update .Eukaryot.
Cell, 4: 633-638.
69- Roncero, C.; Duran, A. (1985) .Effect of calcofluor white
and Congo red on fungal wall morphogenesis: in vivo activation of chitin
polymerization .J,Bacteriol, 170:1950-1954.
70- Rosenberg M.; Judes H.; Weiss E (1983). Celle Surface
Hydrophobicity of Dental Plaques Microorganisms. Infect
Immun. 42(2): 831-834.
71- Rout J.; Rathod V.; Karuppayil (2010). Celle surface
hydrophobicity and adhesion: a study on fifty clinical isolates of Candida
albicans, Jpn J Med Mycol, 51:131-136.
72- Samaranayke, L.P.; Macfarlane, T.W. (1981).The Adhesion
of the yeast Candida albicans to epithelail cells of human origin in
vitro .Arch .Oral Biol ., 26:815-820
Page 7
Références
Bibliographiques
73- Shepherd, M.G.; Poulter, R.T.M.; Sullivan, P.A.
(1985). Candida albicans: biology, genetic and pathogen
city. Ann. Rev Microbiol, 39: 579-614.
74- Samaranayke, Y. H.; Samaranayake, L.P. (1994). Candida
krusei: biology, epidemiology, pathogenicity and clinical manifestations
of an emerging pathogen .J.Med Microbiol,
41:925-310.
75- Sanglard, D.; Odds, F.C. (2002). Resistance of
Candida species to antifungal agents: molecular mechanisms and clinical
consequences .Lancet Infect .Dis, 2: 73-85.
76- Smith, K., Bu, Y.; Suga, H. (2003). Induction and
inhibition of Pseudomonas aeruginasa quorum sensing by synthetic autoinducer
analogs .Chem. Biol, 10:81
77- Sillet. ; Royer S.; Coque Y. and Thomas O. (2001). Les
lixiviats de décharges d'ordures, ménagères :
genèse, composition et traitement. Déchets, Science
et Techniques, 22, 7-11.
78- Vasquez, J.A. ; sobel, J.D. (2002). Mucosal candidiasis
.Infect .Dis .Clin .North.Am., 16: 793-820.
79- Watanabe,T.; Takano, M.; Murakami, M.; Tanaka, H.;
Matsuhisa,A.; Nakao, N.; Mikami, T.;Suzuki,M. Matsumoto ., T.(1999).
Characterization of a haemolytic factor from Candida albicans
.Microbiology, 145:689-694.
80- Wingard, J.R .; Merz, W.G .; Rinaldi, M.G.; Miller , C.B .;
Karp , J.E.; Saral , R.(1993).Association of Torulopsis glabrata infection with
fluconazole prophylaxis in neutropenic bone marrow transplant patients
Antimicrob . Agent Chemother, 37: 1847-1849.
81- White, T.C.; Marr, K.A.; Bowden, R. (1998). Clinical,
cellular, and molecular factors that contribute to antifungal drug
resistance. Clin. Microbiol .Rev, 11:382-402.
82- Wingard, J.R.; Merz, W .G .; Rinaldi , M.G .; Johnson ,
T.R .; Karp, J.E .; Saral , R.(1991). Increase in Candida krusei
infection among patient with bone marrow transplantation and neutropenia
treated prophylactically with fluconazole. N. Engl. J. Med,
18:1274-1277.
83- Wu, T.; Samaranayake, L.P.; Cao, B.Y.; Wang, J. (1996).
In-vitro proteinase production by oral Candida albicans isolates from
individuals with and without HIV infection and its attenuation by antimycotic
agent. Med.Microbiol, 44:311-316.
84- Yi Ping Ge.; Gui Xia Lu.; Yong Nian Shen.; Wei Da Liu
(2011). In Vitro Evaluation of Phospholipase, Proteinase, and Esterase
Activities of Candida parapsilosis and
Candida metapsilosis. Mycopathologia,
172:429-438.
Références
Bibliographiques
Page 8
85- Yigit, N.; Aktas, E (2009). Comparison of the efficacy of
different blood medium in determining the hemolytic activity of
Candida species. Journal de Mycologie
Médicale, 19:
110-115.
. ÏÉÇÖã
ÇÏæã - ??????? -
ÊÇãíÒäÇ - ????? :
ÍíÊÇãáÇ
ÊÇãáßáÇ
| 
